Photo of Joseph Odin

Joseph Odin

  • ASSOCIATE PROFESSOR Medicine, Liver Diseases
Print ProfilePrint Profile

Certifications

  • Gastroenterology

Education

  • MD, Mount Sinai Sch. of Medicine CUNY

  • A.B., Cornell University
    Biology

  • Ph.D., C.U.N.Y.
    Biomedical Sciences

  • Residency, Internal Medicine
    Mount Sinai Hospital

  • Fellowship, Gastroenterology
    Johns Hopkins Hospital

Biography

    Dr. Odin is an associate professor in the Division of Liver Diseases and the Recanati/Miller Transplantation Institute with a clinical background in gastroenterology and liver disease. He is co-director of the Mount Sinai Autoimmune Liver Disease Program. He has research interest in liver autoimmunity and toxicology. His current research studies are focused on novel treatments for primary biliary cirrhosis, primary sclerosing cholangitis and the effect of drugs and toxins on the liver. He cares for individuals with all liver diseases including those with liver transplants. His research is supported by the NIH and he has received past support and awards from the American Gastroenterolofical Association and the American Association for the Study of Liver Disease. He also receives support from pharmaceutical companies for participation in clinical trials examining treatments for viral hepatitis.

    Dr. Odin was recently designated as a Fellow of the American Association for the Study of Liver Diseases (FAASLD) — the highest honor among AASLD membership categories —  which recognizes superior professional achievement in clinical or academic practice, and in basic or clinical research.

    RMTI Website: www.MountSinaiRMTI.org


    Related Resource:
    Autoimmune Liver Disease Treatment Program

Awards

  • 2007 -
    Solomon Silver Award for Clinical Research

  • 2003 -
    Research Excellence in GI and Liver Disease Award

Research

Dr. Odin's liver research focuses on Autoimmune Liver Disease, Toxicity, Fatty Liver Disease, and Viral Hepatitis. Clinical trials and studies are being conducted or planned for primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, drug or toxin induced liver injury, hepatitis B and C, and non-alcoholic fatty liver disease. Some of the research is investigator initiated while other studies are supported by the National Institutes of Health or Pharmaceutical Companies.

Publications

Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, Lu Y, Chen W, Juran BD, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Speiciene D, Vincent C, Levy C, Gregersen PK, Zhang J, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature genetics 2010 Aug; 42(8).

Singal AK, Stanca CM, Clark V, Dixon L, Levy C, Odin JA, Fiel MI, Friedman SL, Bach N. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatology international 2011 Sep; 5(3).

Allina J, Grabowski J, Doherty-Lyons S, Fiel MI, Jackson CE, Zelikoff JT, Odin JA. Maternal allergy acts synergistically with cigarette smoke exposure during pregnancy to induce hepatic fibrosis in adult male offspring. Journal of immunotoxicology; 8(4).

Kesar V, Fiel MI, Odin JA. A lesion in the liver of a 70-year-old woman with right-upper-quadrant discomfort. [abstract]. American Journal of Gastroenterology. 2012;.

Hirschfield GM, Xie G, Lu E, Sun Y, Juran BD, Chellappa V, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Bacon B, Bodenheimer H, Liakina V, Vincent C, Levy C, Pillai S, Lazaridis KN, Amos CI, Siminovitch KA. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes and immunity 2012 Jun; 13(4).

Hu B, Allina J, Bai J, Kesar V, Odin JA. Catalase and estradiol inhibit mitochondrial protein S-glutathionylation. Molecular and cellular biochemistry 2012 Aug; 367(1-2).

Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Heathcote EJ, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, Bossa F, Gershwin ME, deAndrade M, Amos CI, Lazaridis KN, Seldin MF, Siminovitch KA. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Human molecular genetics 2012 Dec; 21(23).

Torres J, Bao X, Iuga AC, Chen A, Harpaz N, Ullman T, Cohen BL, Pineton de Chambrun G, Asciutti S, Odin JA, Sachar DB, Gaskins HR, Setchell K, Colombel JF, Itzkowitz SH. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflammatory bowel diseases 2013 Feb; 19(2).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Odin during 2013 and/or 2014. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Scientific Advisory Board:

  • Bristol-Myers Squibb

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Icahn Medical Institute Floor 4th floor Room 4-89
1425 Madison Avenue
New York, NY 10029


Address

Icahn Medical Institute Floor 4 Room 4-89
1425 Madison Avenue
New York, NY 10029

Tel: 212-289-7738
RMTI - Liver Disease Practice

5 East 98th Street
12th Floor
New York, NY 10029

Tel: 212-241-0034
Fax: 212-731-7340
Get Directions
Languages:
  • Spanish
Insurance Plans
  • Aetna U.S. Healthcare
  • Aetna U.S. Healthcare - HMO
  • Best Doctor
  • Devon Health Services
  • Fidelis Care NY - HMO
  • First Health
  • Group Health Insurance, Inc.
  • Healthnet-Empire BCBS
  • Island Group
  • Medicaid
  • Medicare
  • Neighborhood Health Providers, LLC
  • Oxford Health Plans
  • Railroad Medicare
  • United Healthcare
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Personal Check
  • Cash

RMTI - Liver Trasnplant Practice

5 East 98th Street
12th Floor
New York, NY 10029

Tel: 212-241-8035
Get Directions